Felicita Treatment for Depression & Anxiety

Patent Status (USPTO):

Notice of Allowance and Patent issued.

The Problem
 

For many people, the persistent feeling of sadness or loss of interest is often untreatable with traditional antidepressant medication and can become characterized as Major Depressive Disorder (MDD) or Treatment Resistant Depression (TRD). These are seemingly untreatable cases of depression and can lead to a range of behavioral and physical symptoms. These may include changes in sleep, appetite, energy level, concentration, daily behavior, or self-esteem. Depression can also be associated with suicidal ideation. Anxiety is a mental health disorder characterized by feelings of worry or fear that are strong enough to interfere with one's daily activities. The mainstay of treatment for these conditions is usually medication, talk therapy, or a combination of the two.

 
Solution
 

Synergistic Therapeutics offers Felicita, a medicated sublingual ketamine lozenge to treat anxiety, depression (MDD & TRD), postpartum depression, post traumatic stress disorder (PTSD), bipolar disorder, and other indications of depression.

 
Benefits
 
  • The medication is absorbed via sublingual administration.

  • Shorter administration time than traditional antidepressants. 

  • No pills to ingest that may affect the digestive system.

  • Flavors are added to enhance taste and may improve digestion.

  • Avoids dependency that is often experienced with other available antidepressants.



Why Felicita?
 

Unlike other antidepressant and anti-anxiety treatments, Felicita provides an immediate effect, whereas other therapies that require 4-6 weeks of administration to achieve desired results. Felicita may provide a higher efficacy rate than other therapies while positive effects are immediately realized than current available treatments. This is achieved at the most effective cost compared to other therapies or treatments, including other methods of ketamine delivery.